Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Head & Neck 1Genitourinary 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × zanidatamab × Genitourinary × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡